

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2023/283444 A8

(43) International Publication Date
12 January 2023 (12.01.2023)

WIPO | PCT

(51) International Patent Classification:

A61K 36/185 (2006.01) *A61P 35/00* (2006.01)
A61K 9/06 (2006.01) *A61Q 19/00* (2006.01)
A61K 36/38 (2006.01)

SCHABER, Christopher; 29 Emmons Drive, Suite B-10,
Princeton, NJ 08540 (US).

(74) Agent: **MOYER-HENRY, Kari**; Lewis Kohn & Walker
LLP, 17085 Via Del Campo, San Diego, CA 92127 (US).

(21) International Application Number:

PCT/US2022/036551

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(22) International Filing Date:

08 July 2022 (08.07.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/219,765 08 July 2021 (08.07.2021) US


(71) Applicant: **SOLIGENIX, INC.** [US/US]; 29 Emmons Drive,
Suite B-10, Princeton, NJ 08540 (US).

(72) Inventors: **DONINI, Oreola**; 619 Chapman Avenue, Co-
quitlam, BC V3J 4A2 (CA). **STRAUBE, Richard**; 29
Emmons Drive, Suite B-10, Princeton, NJ 08540 (US).

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

(54) Title: DERMATOLOGICAL COMPOSITIONS AND METHODS OF TREATMENT AGAINST CUTANEOUS T-CELL LYMPHOMA

FIG. 1



(57) Abstract: A method of treating CTCL comprising applying a combination of an effective amount of hypericin together with a form of visible light photodynamic therapy. Preferably, the effective amount of hypericin is an ointment comprising less than 1% hypericin. More preferably, the form of photodynamic therapy comprises an administration of escalating doses of visible light. Optionally, the escalating doses of visible light starts at about 5 J/cm² and increases to a maximum dose of about 12 J/cm².

[Continued on next page]

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

(48) Date of publication of this corrected version:

25 May 2023 (25.05.2023)

(15) Information about Correction:

see Notice of 25 May 2023 (25.05.2023)